Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Consta for Relapse Prevention in Bipolar Disorder
NCT00571688Phase 4Completed
- Sponsor
- Vanderbilt University
- Start
- Nov 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone in bipolar disorder (BD) (2 arms), sponsored by Vanderbilt University. Primary endpoint: Number of Relapse-related Events Normalized to Unit Time at 12 months. Started Nov 2007; status: completed.
02
Drugs
risperidone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00571688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571688.